Retargeting of Viruses to Generate Oncolytic Agents

Oncolytic virus therapy is based on the ability of viruses to effectively infect and kill tumor cells without destroying the normal tissues. While some viruses seem to have a natural preference for tumor cells, most viruses require the modification of their tropism to specifically enter and replicat...

Full description

Bibliographic Details
Main Authors: Verheije, M. H., Rottier, P. J. M.
Format: Online
Language:English
Published: Hindawi Publishing Corporation 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265223/
id pubmed-3265223
recordtype oai_dc
spelling pubmed-32652232012-02-06 Retargeting of Viruses to Generate Oncolytic Agents Verheije, M. H. Rottier, P. J. M. Review Article Oncolytic virus therapy is based on the ability of viruses to effectively infect and kill tumor cells without destroying the normal tissues. While some viruses seem to have a natural preference for tumor cells, most viruses require the modification of their tropism to specifically enter and replicate in such cells. This review aims to describe the transductional targeting strategies currently employed to specifically redirect viruses towards surface receptors on tumor cells. Three major strategies can be distinguished; they involve (i) the incorporation of new targeting specificity into a viral surface protein, (ii) the incorporation of a scaffold into a viral surface protein to allow the attachment of targeting moieties, and (iii) the use of bispecific adapters to mediate targeting of a virus to a specified moiety on a tumor cell. Of each strategy key features, advantages and limitations are discussed and examples are given. Because of their potential to cause sustained, multiround infection—a desirable characteristic for eradicating tumors—particular attention is given to viruses engineered to become self-targeted by the genomic expression of a bispecific adapter protein. Hindawi Publishing Corporation 2012 2011-11-14 /pmc/articles/PMC3265223/ /pubmed/22312365 http://dx.doi.org/10.1155/2012/798526 Text en Copyright © 2012 M. H. Verheije and P. J. M. Rottier. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Verheije, M. H.
Rottier, P. J. M.
spellingShingle Verheije, M. H.
Rottier, P. J. M.
Retargeting of Viruses to Generate Oncolytic Agents
author_facet Verheije, M. H.
Rottier, P. J. M.
author_sort Verheije, M. H.
title Retargeting of Viruses to Generate Oncolytic Agents
title_short Retargeting of Viruses to Generate Oncolytic Agents
title_full Retargeting of Viruses to Generate Oncolytic Agents
title_fullStr Retargeting of Viruses to Generate Oncolytic Agents
title_full_unstemmed Retargeting of Viruses to Generate Oncolytic Agents
title_sort retargeting of viruses to generate oncolytic agents
description Oncolytic virus therapy is based on the ability of viruses to effectively infect and kill tumor cells without destroying the normal tissues. While some viruses seem to have a natural preference for tumor cells, most viruses require the modification of their tropism to specifically enter and replicate in such cells. This review aims to describe the transductional targeting strategies currently employed to specifically redirect viruses towards surface receptors on tumor cells. Three major strategies can be distinguished; they involve (i) the incorporation of new targeting specificity into a viral surface protein, (ii) the incorporation of a scaffold into a viral surface protein to allow the attachment of targeting moieties, and (iii) the use of bispecific adapters to mediate targeting of a virus to a specified moiety on a tumor cell. Of each strategy key features, advantages and limitations are discussed and examples are given. Because of their potential to cause sustained, multiround infection—a desirable characteristic for eradicating tumors—particular attention is given to viruses engineered to become self-targeted by the genomic expression of a bispecific adapter protein.
publisher Hindawi Publishing Corporation
publishDate 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265223/
_version_ 1611501947030863872